



REGULATED INFORMATION • REGULATED INFORMATION • REGULATED INFORMATION

HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT

Paris and Boston, January 8, 2016 - Neovacs (Alternext Paris : ALNEV) releases its six-monthly report on the liquidity contract signed with Invest Securities.

The liquidity account had the following holdings as of December 31, 2015:

- 36,958 shares
- €164.942,27

For the prior (June 30, 2015), the corresponding figures were:

- 73,818 shares
- €119.469,22

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α -Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

For more information on Neovacs, please visit www.neovacs.fr

Contacts

NEOVACS – Corporate Communication & Investor Relations

Charlène Masson

+33 (0)1 53 10 93 14

cmasson@neovacs.com

Investor Relations / Financial Communications – NewCap

Valentine Brouchet / Pierre Laurent

+33 (0)1 44 71 94 94

neovacs@newcap.eu